Business Context and Reporting Period
This Form 8-K filing by Pfizer Inc. reports a material corporate governance event dated June 18, 2026. The filing addresses the upcoming departure of the Chief Financial Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Dave Denton notified the Company on June 16, 2026, that he will step down as Chief Financial Officer effective August 15, 2026.
- Reason for Departure: Mr. Denton is leaving for a professional opportunity in the consumer goods industry. The filing explicitly states the departure is not related to financial results or disagreements regarding accounting or reporting policies.
- Interim Appointment: Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer effective August 16, 2026.
Outlook, Risks, and Management Commentary
Management has initiated a comprehensive process to identify a permanent successor to Mr. Denton. Ms. Guegan, who joined Pfizer in 2005 and has held her current role since 2022, will lead the finance function during the transition. No specific risks or contingencies related to financial operations were disclosed in this filing.
Investor Verification Checklist
- Verify the exact transition date of August 15, 2026, for the CFO role change.
- Review the attached press release (Exhibit 99.1) for additional details on the search for a permanent CFO.
- Monitor future filings for the announcement of the permanent Chief Financial Officer appointment.
- Confirm that no other executive departures are linked to this event.